ADA2026: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy

Bioage Labs Inc. published this content on June 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 09, 2026 at 00:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]